0001967249-23-000001.txt : 20230301 0001967249-23-000001.hdr.sgml : 20230301 20230301163659 ACCESSION NUMBER: 0001967249-23-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20230301 DATE AS OF CHANGE: 20230301 EFFECTIVENESS DATE: 20230301 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ascend Gene & Cell Therapies Ltd. CENTRAL INDEX KEY: 0001967249 IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-474622 FILM NUMBER: 23694233 BUSINESS ADDRESS: STREET 1: 1 ASHLEY ROAD STREET 2: 3RD FLOOR CITY: ALTRINCHAM STATE: X0 ZIP: WA14 2DT BUSINESS PHONE: 020-814-83794 MAIL ADDRESS: STREET 1: 1 ASHLEY ROAD STREET 2: 3RD FLOOR CITY: ALTRINCHAM STATE: X0 ZIP: WA14 2DT D 1 primary_doc.xml X0708 D LIVE 0001967249 Ascend Gene & Cell Therapies Ltd. 1 ASHLEY ROAD 3RD FLOOR ALTRINCHAM X0 UNITED KINGDOM WA14 2DT 020-814-83794 UNITED KINGDOM None None Corporation true 2021 Fred Cohen c/o Ascend Gene & Cell Therapies Ltd. 1 Ashley Road, 3rd Floor Altrincham X0 UNITED KINGDOM WA14 2DT Director Timothy Funnell c/o Ascend Gene & Cell Therapies Ltd. 1 Ashley Road, 3rd Floor Altrincham X0 UNITED KINGDOM WA14 2DT Executive Officer Director Andrew May c/o Ascend Gene & Cell Therapies Ltd. 1 Ashley Road, 3rd Floor Altrincham X0 UNITED KINGDOM WA14 2DT Director Balaji Muralidhar c/o Ascend Gene & Cell Therapies Ltd. 1 Ashley Road, 3rd Floor Altrincham X0 UNITED KINGDOM WA14 2DT Director Andrew Sinclair c/o Ascend Gene & Cell Therapies Ltd. 1 Ashley Road, 3rd Floor Altrincham X0 UNITED KINGDOM WA14 2DT Director Michael Beecham c/o Ascend Gene & Cell Therapies Ltd. 1 Ashley Road, 3rd Floor Altrincham X0 UNITED KINGDOM WA14 2DT Director Eric Shiozaki c/o Ascend Gene & Cell Therapies Ltd. 1 Ashley Road, 3rd Floor Altrincham X0 UNITED KINGDOM WA14 2DT Director Other Decline to Disclose 06b false 2023-02-07 false true false 0 66624999 66624999 0 false 10 0 0 0 false Ascend Gene & Cell Therapies Ltd. /s/ Timothy Funnell Timothy Funnell Chief Executive Officer 2023-03-01